MYBIOTICS PHARMA LTD

Their core work

Mybiotics Pharma is an Israeli biotech SME developing proprietary technologies for targeted delivery of personalized probiotics to the human gut. Their core work addresses microbiome dysbiosis — the imbalance of gut bacteria linked to antibiotic-associated diarrhea, chronic disease, and other conditions where standard dietary supplements fall short. They started by formulating probiotic food supplements to prevent antibiotic-associated disorders, then advanced to a platform technology (MBSelect) that enables efficient, personalized delivery of live bacteria. Their work sits at the intersection of pharmaceutical-grade precision and the fast-growing microbiome therapeutics space.

What they specialise in

How they've shifted over time

Mybiotics began in 2016 with a narrow, product-focused Phase 1 grant — a probiotic food supplement for a specific indication (antibiotic-associated disorders). By 2020, they had matured into platform technology: MBSelect is not a product but a delivery system enabling personalization, which is a fundamentally different level of technological ambition. The keyword set from their later project — dysbiosis, FMT, chronic disease, personalized medicine, pharmaceutical — shows a deliberate shift from nutraceutical toward pharma-grade microbiome therapeutics.

Mybiotics is moving up the value chain from consumer dietary supplements toward precision microbiome therapeutics, positioning themselves as a technology platform company rather than a product manufacturer.

How they like to work

Mybiotics has operated exclusively as a solo coordinator on both H2020 projects, which is typical of the SME Instrument scheme — designed for single companies proving and scaling their own innovations. They have not built a consortium network in the EU project context, meaning they are an independent innovator rather than a habitual consortium partner. A future collaborator should expect to work with a company that is accustomed to driving its own agenda and may need to adapt to consortium dynamics.

Within the H2020 programme, Mybiotics has no recorded consortium partners — both grants were solo SME Instrument awards. Their collaboration footprint is limited to the Israeli national research ecosystem and EU-Israeli bilateral ties enabled by Israel's Horizon association status.

What sets them apart

Mybiotics is one of very few Israeli SMEs in the H2020 microbiome space that progressed from Phase 1 concept validation all the way to a Phase 2 platform development grant — demonstrating both scientific credibility and commercial traction sufficient to secure EUR 2M from the European Commission. Their MBSelect platform addresses a genuine gap: most probiotics on the market are not personalized and lack targeted gut delivery, which Mybiotics explicitly solves. For consortia targeting microbiome-based health solutions, they bring proprietary delivery IP and pharmaceutical development experience from outside the typical EU academic cluster.

Highlights from their portfolio

• MBSelect
  The largest grant (EUR 1.99M, SME Phase 2) and the project that elevates Mybiotics from supplement maker to platform technology company — their personalized probiotic delivery system targets a broad range of gut-related chronic diseases and includes FMT-related approaches.
• AB-Prevention
  An early-stage feasibility grant (EUR 50K, SME Phase 1) that validated the antibiotic-associated dysbiosis concept and served as the foundation for the much larger MBSelect development project four years later.